These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 8815594)

  • 21. rFactor VIII deficit questioned.
    Garber K
    Nat Biotechnol; 2000 Nov; 18(11):1133. PubMed ID: 11062420
    [No Abstract]   [Full Text] [Related]  

  • 22. Economic issues in European self-sufficiency.
    Szucs TD
    Blood Coagul Fibrinolysis; 1994 Dec; 5 Suppl 4():S51-5. PubMed ID: 7795140
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Health status in Iranian haemophilic patients.
    Karimi M; Rahmani S; Ardeshiri R; Pasalar M
    Haemophilia; 2008 May; 14(3):615-7. PubMed ID: 18393983
    [No Abstract]   [Full Text] [Related]  

  • 24. Recombinant factor VIII in hemophilia A: the Canadian experience.
    Blanchette VS
    Blood Coagul Fibrinolysis; 1997 Aug; 8 Suppl 1():S33-9. PubMed ID: 9351535
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Factor VIII concentrate available for treatment of classical hemophilia.
    Jewett WR
    Ann N Y Acad Sci; 1975 Jan; 240():188-90. PubMed ID: 1053863
    [No Abstract]   [Full Text] [Related]  

  • 26. Firm behavior in the U.S. market for factor VIII: a need for policy?
    Nauenberg E; Sullivan SD
    Soc Sci Med; 1994 Dec; 39(12):1591-603. PubMed ID: 7846556
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Hemophilia therapy with plasma fractions. Milan, April 23, 1968].
    Policlinico Prat; 1968 Jul; 75(31):1017-9. PubMed ID: 5735880
    [No Abstract]   [Full Text] [Related]  

  • 28. Pfizer and Sangamo Hemophilia A Gene Therapy Aces First Clinical Test.
    Philippidis A
    Hum Gene Ther; 2020 Jul; 31(13-14):705-708. PubMed ID: 32716734
    [No Abstract]   [Full Text] [Related]  

  • 29. Is a change of factor VIII product a risk factor for the development of a factor VIII inhibitor?
    Baglin T; Beacham E
    Thromb Haemost; 1998 Dec; 80(6):1036-7. PubMed ID: 9869186
    [No Abstract]   [Full Text] [Related]  

  • 30. Guam's quest for improved hemophilia care.
    Zabala RV; Baker JR
    Pac Health Dialog; 2002 Sep; 9(2):317-20. PubMed ID: 14736122
    [No Abstract]   [Full Text] [Related]  

  • 31. Successful surgery in severe haemophilia--a two-stage replacement therapy in resource-poor countries.
    Prabhu R; Jijina F; Shetty S; Ghosh K
    Haemophilia; 2008 Sep; 14(5):1125-6. PubMed ID: 18625030
    [No Abstract]   [Full Text] [Related]  

  • 32. Freeze dried cryoprecipitate: a clinical evaluation.
    Hambley H; Davidson JF; Walker ID; Small M; Prentice CR
    J Clin Pathol; 1983 May; 36(5):574-6. PubMed ID: 6404949
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-effectiveness in establishing hemophilia carrier detection and prenatal diagnosis services in a developing country with limited health resources.
    Sasanakul W; Chuansumrit A; Ajjimakorn S; Krasaesub S; Sirachainan N; Chotsupakarn S; Kadegasem P; Rurgkhum S
    Southeast Asian J Trop Med Public Health; 2003 Dec; 34(4):891-8. PubMed ID: 15115107
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Letter: Treatment of haemophilia.
    Blackburn EK
    Lancet; 1974 Jul; 2(7872):105. PubMed ID: 4137023
    [No Abstract]   [Full Text] [Related]  

  • 35. Supply and demand for hemophilia treatments-Systems-based approaches to mitigate the risk.
    Stoffman JM; Jackson S; Teitel J
    Transfus Apher Sci; 2018 Dec; 57(6):731-734. PubMed ID: 30391093
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibitors of factor VIII in hemophilia.
    Eckhardt CL; Kamphuisen PW; Fijnvandraat K
    N Engl J Med; 2009 Jul; 361(3):309; author reply 310. PubMed ID: 19610163
    [No Abstract]   [Full Text] [Related]  

  • 37. Observations from Global Survey 2001: an emerging database for progress.
    Evatt BL
    Haemophilia; 2002 Mar; 8(2):153-6. PubMed ID: 11952853
    [No Abstract]   [Full Text] [Related]  

  • 38. Coagulation factor VIII concentrates and the marketplace.
    Cash JD
    Lancet; 1988 Jun; 1(8597):1270. PubMed ID: 2897528
    [No Abstract]   [Full Text] [Related]  

  • 39. Hemophilia factor VIII therapy. Immunological tolerance. A clinical perspective.
    White GC; Greenwood R; Escobar M; Frelinger JA
    Haematologica; 2000 Oct; 85(10 Suppl):113-6. PubMed ID: 11187862
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In that case.
    Anderson L; Cunningham N
    J Bioeth Inq; 2005; 2(2):109. PubMed ID: 16317869
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.